MX2015011362A - Metodo para el pronostico y tratamiento de metastasis de cancer. - Google Patents
Metodo para el pronostico y tratamiento de metastasis de cancer.Info
- Publication number
- MX2015011362A MX2015011362A MX2015011362A MX2015011362A MX2015011362A MX 2015011362 A MX2015011362 A MX 2015011362A MX 2015011362 A MX2015011362 A MX 2015011362A MX 2015011362 A MX2015011362 A MX 2015011362A MX 2015011362 A MX2015011362 A MX 2015011362A
- Authority
- MX
- Mexico
- Prior art keywords
- relates
- cancer
- bone metastases
- gene
- interest
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- G01N33/57557—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801718P | 2013-03-15 | 2013-03-15 | |
| PCT/IB2014/001253 WO2014140933A2 (en) | 2013-03-15 | 2014-03-14 | Method for the prognosis and treatment of cancer metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015011362A true MX2015011362A (es) | 2015-12-16 |
Family
ID=51265712
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011362A MX2015011362A (es) | 2013-03-15 | 2014-03-14 | Metodo para el pronostico y tratamiento de metastasis de cancer. |
| MX2020001156A MX2020001156A (es) | 2013-03-15 | 2015-09-02 | Metodo para el pronostico y tratamiento de metastasis de cancer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001156A MX2020001156A (es) | 2013-03-15 | 2015-09-02 | Metodo para el pronostico y tratamiento de metastasis de cancer. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160032400A1 (enExample) |
| EP (1) | EP2971113B1 (enExample) |
| JP (1) | JP6577873B2 (enExample) |
| KR (1) | KR20150122731A (enExample) |
| CN (1) | CN105324491B (enExample) |
| AU (1) | AU2014229505B2 (enExample) |
| BR (1) | BR112015023783A2 (enExample) |
| CA (1) | CA2906394A1 (enExample) |
| MX (2) | MX2015011362A (enExample) |
| WO (1) | WO2014140933A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8338109B2 (en) | 2006-11-02 | 2012-12-25 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| US20110136683A1 (en) | 2008-05-28 | 2011-06-09 | Genomedx Biosciences, Inc. | Systems and Methods for Expression-Based Discrimination of Distinct Clinical Disease States in Prostate Cancer |
| US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US9074258B2 (en) | 2009-03-04 | 2015-07-07 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
| US8669057B2 (en) | 2009-05-07 | 2014-03-11 | Veracyte, Inc. | Methods and compositions for diagnosis of thyroid conditions |
| US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
| WO2012045905A2 (es) | 2010-10-06 | 2012-04-12 | Fundació Privada Institut De Recerca Biomèdica | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama |
| US20130267443A1 (en) | 2010-11-19 | 2013-10-10 | The Regents Of The University Of Michigan | ncRNA AND USES THEREOF |
| EP2791359B1 (en) | 2011-12-13 | 2020-01-15 | Decipher Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| KR102226219B1 (ko) | 2012-06-06 | 2021-03-10 | 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) | 폐암 전이의 진단, 예후 및 치료 방법 |
| US11035005B2 (en) | 2012-08-16 | 2021-06-15 | Decipher Biosciences, Inc. | Cancer diagnostics using biomarkers |
| JP6074049B2 (ja) | 2012-10-12 | 2017-02-01 | インバイオモーション エセ．エレ． | ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法 |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| EP3626308A1 (en) | 2013-03-14 | 2020-03-25 | Veracyte, Inc. | Methods for evaluating copd status |
| US20140314792A1 (en) | 2013-03-15 | 2014-10-23 | Institució Catalana De Recerca I Estudis Avançats | Method for the diagnosis, prognosis and treatment of cancer metastasis |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US20170335396A1 (en) | 2014-11-05 | 2017-11-23 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
| BR112017012515A2 (en) | 2014-12-11 | 2018-01-02 | Inbiomotion S.L. | binding members for human c-maf |
| CN109069634A (zh) * | 2016-02-18 | 2018-12-21 | 国立大学法人京都大学 | 能够抑制外泌体中的遗传功能的复合物以及癌症增殖和/或转移抑制剂 |
| US11013817B2 (en) * | 2016-04-08 | 2021-05-25 | The Cleveland Clinic Foundation | Nanoparticles for drug delivery to treat bone disease |
| CA3023976A1 (en) * | 2016-05-19 | 2017-11-23 | Probiocon Gmbh | Anti-cancer combination treatment |
| PL3458610T3 (pl) * | 2016-05-25 | 2021-11-22 | Inbiomotion S.L. | Leczenie raka piersi w oparciu o status c-MAF |
| KR20190028726A (ko) * | 2016-07-12 | 2019-03-19 | 더 유니버시티 오브 노스캐롤라이나 앳 채플 힐 | 암 진단 및 모델링에 사용하기 위한 바이오매트릭스 스캐폴드 |
| WO2018039490A1 (en) | 2016-08-24 | 2018-03-01 | Genomedx Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
| AU2018210695B2 (en) | 2017-01-20 | 2024-07-18 | The University Of British Columbia | Molecular subtyping, prognosis, and treatment of bladder cancer |
| EP3593140A4 (en) | 2017-03-09 | 2021-01-06 | Decipher Biosciences, Inc. | SUBTYPING PROSTATE CANCER TO PREDICT RESPONSE TO HORMONE THERAPY |
| EP3622087A4 (en) | 2017-05-12 | 2021-06-16 | Decipher Biosciences, Inc. | GENETIC SIGNATURES FOR PREDICTING PROSTATE CANCER METASTASIS AND IDENTIFYING TUMOR AGGRESSIVITY |
| US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
| US12497660B2 (en) | 2017-08-04 | 2025-12-16 | Veracyte SD, Inc. | Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy |
| BR112020010192A2 (pt) | 2017-11-22 | 2020-10-13 | Inbiomotion S.L. | tratamento terapêutico de câncer de mama com base no status de c-maf |
| CN108084254A (zh) * | 2017-11-30 | 2018-05-29 | 天津市湖滨盘古基因科学发展有限公司 | 一种人的抗癌基因WWOXδ6-8突变蛋白及其应用 |
| WO2021185959A1 (en) * | 2020-03-19 | 2021-09-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Estrogen-related receptor alpha agonists for the treatment and the prognosis of bone metastases |
| CN115198013A (zh) * | 2021-04-14 | 2022-10-18 | 迪瑞药业(成都)有限公司 | 用以鉴别出适用精氨酸剥夺疗法的患者的方法与试剂盒 |
| WO2024168137A1 (en) * | 2023-02-08 | 2024-08-15 | Iogenetics, Llc | Cleaved neoepitopes |
| CN115919464B (zh) * | 2023-03-02 | 2023-06-23 | 四川爱麓智能科技有限公司 | 肿瘤定位方法、系统、装置及肿瘤发展预测方法 |
| CN119614707A (zh) * | 2025-01-13 | 2025-03-14 | 中山大学 | ERα生物标志物在ER+乳腺癌骨转移诊断、治疗和预后中的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE89314T1 (de) | 1985-02-13 | 1993-05-15 | Scios Nova Inc | Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| JP2000508895A (ja) | 1996-04-05 | 2000-07-18 | ザ ソールク インスチチュート フォア バイオロジカル スタディズ | 哺乳動物系における外来遺伝子の発現を調節するためのホルモン媒介方法と、それに関連した産物 |
| CA2274987C (en) | 1996-12-23 | 2012-01-24 | Immunex Corporation | Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| EE04911B1 (et) | 1999-03-15 | 2007-10-15 | Axys Pharmaceuticals, Inc. | Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks |
| US6287813B1 (en) | 1999-04-23 | 2001-09-11 | Cistronics Cell Technology Gmbh | Antibiotic-based gene regulation system |
| US6525036B2 (en) | 2000-01-06 | 2003-02-25 | Merck & Co., Inc. | Compounds and compositions as protease inhibitors |
| US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| DK2087908T3 (en) | 2001-06-26 | 2018-07-23 | Amgen Inc | ANTIBODIES AGAINST OPGL |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| AU2003903540A0 (en) | 2003-07-09 | 2003-07-24 | Atdec Pty Ltd | Flat panel display wall mounting system |
| WO2005026322A2 (en) | 2003-09-11 | 2005-03-24 | Clontech Laboratories, Inc. | siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME |
| AU2003286499A1 (en) | 2003-10-17 | 2004-06-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| US20090048117A1 (en) | 2003-12-18 | 2009-02-19 | President And Fellows Of Harvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| TW200526224A (en) | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| US20080131940A1 (en) | 2004-06-25 | 2008-06-05 | Robert Chiu | Target Cell-Specific Short Interfering Rna and Methods of Use Thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| EP1969000A2 (en) | 2005-12-06 | 2008-09-17 | Centre National de la Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| EP1984024A2 (en) * | 2006-01-05 | 2008-10-29 | Novartis AG | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| US8623361B2 (en) | 2007-05-24 | 2014-01-07 | Ablynx N.V. | Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders |
| US8728738B2 (en) * | 2008-07-02 | 2014-05-20 | Assistance Publique-Hopitaux De Paris | Method for predicting clinical outcome of patients with non-small cell lung carcinoma |
| WO2012045905A2 (es) * | 2010-10-06 | 2012-04-12 | Fundació Privada Institut De Recerca Biomèdica | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama |
| WO2012064967A2 (en) * | 2010-11-10 | 2012-05-18 | Cedars-Sinai Medical Center | Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases |
| EP2650682A1 (en) * | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| KR102226219B1 (ko) * | 2012-06-06 | 2021-03-10 | 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) | 폐암 전이의 진단, 예후 및 치료 방법 |
-
2014
- 2014-03-14 AU AU2014229505A patent/AU2014229505B2/en active Active
- 2014-03-14 JP JP2015562411A patent/JP6577873B2/ja active Active
- 2014-03-14 CA CA2906394A patent/CA2906394A1/en active Pending
- 2014-03-14 KR KR1020157026432A patent/KR20150122731A/ko not_active Ceased
- 2014-03-14 EP EP14747411.8A patent/EP2971113B1/en active Active
- 2014-03-14 CN CN201480015564.0A patent/CN105324491B/zh active Active
- 2014-03-14 WO PCT/IB2014/001253 patent/WO2014140933A2/en not_active Ceased
- 2014-03-14 BR BR112015023783A patent/BR112015023783A2/pt not_active Application Discontinuation
- 2014-03-14 MX MX2015011362A patent/MX2015011362A/es unknown
- 2014-03-14 US US14/776,412 patent/US20160032400A1/en not_active Abandoned
-
2015
- 2015-09-02 MX MX2020001156A patent/MX2020001156A/es unknown
-
2021
- 2021-04-27 US US17/241,571 patent/US20210317534A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150122731A (ko) | 2015-11-02 |
| CN105324491B (zh) | 2021-10-26 |
| EP2971113B1 (en) | 2020-08-12 |
| WO2014140933A3 (en) | 2014-12-31 |
| JP6577873B2 (ja) | 2019-09-18 |
| AU2014229505B2 (en) | 2020-02-27 |
| EP2971113A2 (en) | 2016-01-20 |
| JP2016516403A (ja) | 2016-06-09 |
| WO2014140933A8 (en) | 2020-10-01 |
| US20160032400A1 (en) | 2016-02-04 |
| WO2014140933A2 (en) | 2014-09-18 |
| BR112015023783A2 (pt) | 2017-10-24 |
| AU2014229505A1 (en) | 2015-09-03 |
| US20210317534A1 (en) | 2021-10-14 |
| CN105324491A (zh) | 2016-02-10 |
| MX2020001156A (es) | 2020-03-12 |
| CA2906394A1 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015011362A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| WO2013153458A3 (en) | Method for the prognosis and treatment of cancer metastasis | |
| MX2019000091A (es) | Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. | |
| MX2015004610A (es) | Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf. | |
| AR083357A1 (es) | Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama | |
| BR112014030750A2 (pt) | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| WO2014184679A3 (en) | Method for the prognosis and treatment of renal cell carcinoma metastasis | |
| MX366164B (es) | Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata. | |
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| MX390772B (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| NZ599194A (en) | Methods to predict clinical outcome of cancer | |
| MA39776A (fr) | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf | |
| MX2015015605A (es) | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. | |
| BR112016013976A2 (pt) | método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método | |
| UY36200A (es) | Conjunto de biomarcadores específicos para diagnóstico no invasivo de cáncer de hígado | |
| MX2017006075A (es) | Biomarcadores para la progresion de enfermedades en melanoma. | |
| PH12015500388A1 (en) | Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells | |
| EP4265740A3 (en) | Methods for predicting risk of metastasis in cutaneous melanoma | |
| GB2523211A8 (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
| MX2018009112A (es) | Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer mediante la medicion del nivel de un biomarcador plasmatico. | |
| EA202090439A1 (ru) | Способы и материалы для оценки и лечения рака | |
| UY31535A1 (es) | Método para diagnosticar tumores colorrectales | |
| UY31534A1 (es) | Metodo para diagnosticar tumores colorrectales | |
| TR201407357A2 (tr) | Prostat kanserinin tekrarlama potansiyelini tahmin yöntemi. |